Format

Send to

Choose Destination
Int J Pharm. 2013 Oct 15;455(1-2):298-305. doi: 10.1016/j.ijpharm.2013.07.014. Epub 2013 Jul 24.

In vitro evaluation of TiO2 nanotubes as cefuroxime carriers on orthopaedic implants for the prevention of periprosthetic joint infections.

Author information

1
EA 4676 C-BIOSENSS, Clermont Université, Université d'Auvergne, BP 10448, F-63000 Clermont-Ferrand, France. pchennell@chu-clermontferrand.fr

Abstract

CONTEXT:

The prevention of periprosthetic joint infections requires an antibiotic prophylactic therapy, which could be delivered locally using titanium dioxide nanotubes as novel reservoirs created directly on the orthopaedic implant titanium surface.

OBJECTIVE:

In this study, the influence of several parameters that could impact the use of titanium dioxide nanotubes as cefuroxime carriers was investigated.

METHOD:

Cefuroxime loading and release was studied for 90 min with three nano-topography conditions (nano-smooth, nano-rugged and nano-tubular), two cefuroxime loading solution concentrations (150 mg/mL and 25mg/mL) and two nano-tubular crystalline structures.

RESULTS:

In all tested conditions, maximum amount of cefuroxime was obtained within 2 min. For both cefuroxime loading solution concentrations, nano-smooth samples released the least cefuroxime, and the nano-tubular samples released the most, and a six-fold increase in the concentration of the cefuroxime loading increased the amount of cefuroxime quantified by more than seven times, for all tested nano-topographies. However, the nano-tubes' crystalline structure did not have any influence on the amount of cefuroxime quantified.

CONCLUSION:

The results demonstrated that the surface nano-topography and loading solution concentration influence the efficiency of titanium dioxide nanotubes as cefuroxime carriers and need to be optimized for use as novel reservoirs for local delivery of cefuroxime to prevent periprosthetic infections.

KEYWORDS:

Cefuroxime; Drug delivery systems; Nanotubes; Periprosthetic joint infections; Titanium dioxide

PMID:
23892151
DOI:
10.1016/j.ijpharm.2013.07.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center